Tags

Type your tag names separated by a space and hit enter

An inhibition of the hypothalamic somatostatinergic tone is not the cause of the enhanced growth hormone response to growth hormone-releasing hormone in patients with liver cirrhosis.
Exp Clin Endocrinol Diabetes. 2008 Mar; 116(3):148-51.EC

Abstract

Animal models of liver cirrhosis (LC) display a reduced hypothalamic somatostatinergic tone. To test whether a similar mechanism could explain the enhanced Growth Hormone (GH) secretory response to GH-Releasing Hormone (GHRH), which is seen in human LC, we studied the effect of the cholinesterase inhibitor pyridostigmine (PD), which is able to reduce the release of hypothalamic somatostatin (SS), on the GHRH-stimulated GH secretion. We considered that if PD were unable to increase GH secretion, this would constitute evidence of an already inhibited endogenous somatostatinergic tone. If proved, this in turn could explain the enhanced GH response to GHRH seen in LC. Ten LC patients and nine controls were given GHRH (100 microg, intravenously), or PD (120 mg, orally) plus GHRH. After GHRH alone, the GH peak was four times higher in LC than in controls (40.85+/-15.7 ng/ml in LC and 9.35+/-2.5 ng/ml in controls). In LC, PD administration markedly increased the GH response to GHRH (GH peak: 98.0+/-19.7 ng/ml; +240% vs. GHRH alone). The ability of PD to increase the GH response in patients with LC suggests that in this condition the enhanced GH response to GHRH is not due to a completely inhibited endogenous somatostatinergic tone. SS appears instead to maintain its modulator role on GH secretion in human LC, in contrast with what observed in animal models.

Authors+Show Affiliations

Dipartimento-Struttura Clinica Medica - Patologia Speciale Medica, University of Sassari, Sassari, Italy. gfanciu@uniss.itNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article

Language

eng

PubMed ID

18095239

Citation

Fanciulli, G, et al. "An Inhibition of the Hypothalamic Somatostatinergic Tone Is Not the Cause of the Enhanced Growth Hormone Response to Growth Hormone-releasing Hormone in Patients With Liver Cirrhosis." Experimental and Clinical Endocrinology & Diabetes : Official Journal, German Society of Endocrinology [and] German Diabetes Association, vol. 116, no. 3, 2008, pp. 148-51.
Fanciulli G, Tomasi PA, Giusti M, et al. An inhibition of the hypothalamic somatostatinergic tone is not the cause of the enhanced growth hormone response to growth hormone-releasing hormone in patients with liver cirrhosis. Exp Clin Endocrinol Diabetes. 2008;116(3):148-51.
Fanciulli, G., Tomasi, P. A., Giusti, M., Bertoncelli, A., Deplano, A., Garrucciu, G., & Delitala, G. (2008). An inhibition of the hypothalamic somatostatinergic tone is not the cause of the enhanced growth hormone response to growth hormone-releasing hormone in patients with liver cirrhosis. Experimental and Clinical Endocrinology & Diabetes : Official Journal, German Society of Endocrinology [and] German Diabetes Association, 116(3), 148-51.
Fanciulli G, et al. An Inhibition of the Hypothalamic Somatostatinergic Tone Is Not the Cause of the Enhanced Growth Hormone Response to Growth Hormone-releasing Hormone in Patients With Liver Cirrhosis. Exp Clin Endocrinol Diabetes. 2008;116(3):148-51. PubMed PMID: 18095239.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - An inhibition of the hypothalamic somatostatinergic tone is not the cause of the enhanced growth hormone response to growth hormone-releasing hormone in patients with liver cirrhosis. AU - Fanciulli,G, AU - Tomasi,P A, AU - Giusti,M, AU - Bertoncelli,A, AU - Deplano,A, AU - Garrucciu,G, AU - Delitala,G, Y1 - 2007/12/20/ PY - 2007/12/21/pubmed PY - 2008/8/16/medline PY - 2007/12/21/entrez SP - 148 EP - 51 JF - Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association JO - Exp. Clin. Endocrinol. Diabetes VL - 116 IS - 3 N2 - Animal models of liver cirrhosis (LC) display a reduced hypothalamic somatostatinergic tone. To test whether a similar mechanism could explain the enhanced Growth Hormone (GH) secretory response to GH-Releasing Hormone (GHRH), which is seen in human LC, we studied the effect of the cholinesterase inhibitor pyridostigmine (PD), which is able to reduce the release of hypothalamic somatostatin (SS), on the GHRH-stimulated GH secretion. We considered that if PD were unable to increase GH secretion, this would constitute evidence of an already inhibited endogenous somatostatinergic tone. If proved, this in turn could explain the enhanced GH response to GHRH seen in LC. Ten LC patients and nine controls were given GHRH (100 microg, intravenously), or PD (120 mg, orally) plus GHRH. After GHRH alone, the GH peak was four times higher in LC than in controls (40.85+/-15.7 ng/ml in LC and 9.35+/-2.5 ng/ml in controls). In LC, PD administration markedly increased the GH response to GHRH (GH peak: 98.0+/-19.7 ng/ml; +240% vs. GHRH alone). The ability of PD to increase the GH response in patients with LC suggests that in this condition the enhanced GH response to GHRH is not due to a completely inhibited endogenous somatostatinergic tone. SS appears instead to maintain its modulator role on GH secretion in human LC, in contrast with what observed in animal models. SN - 0947-7349 UR - https://www.unboundmedicine.com/medline/citation/18095239/An_inhibition_of_the_hypothalamic_somatostatinergic_tone_is_not_the_cause_of_the_enhanced_growth_hormone_response_to_growth_hormone_releasing_hormone_in_patients_with_liver_cirrhosis_ L2 - http://www.thieme-connect.com/DOI/DOI?10.1055/s-2007-992119 DB - PRIME DP - Unbound Medicine ER -